Drugs / ACE-2494
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03478319 | Feb 2018 → Jun 2019 | — | Acceleron Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE-2494 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03478319 ↗ |
| Modality | Protein / enzyme biologic | “Recombination fusion protein” NCT03478319 ↗ |
| Route | Subcutaneous | “ACE-2494 or placebo 0.06 mg/kg SC Day 1” NCT03478319 ↗ |